These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 26018461

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.
    Yuan S, Palmer JM, Tsai NC, Dagis A, Nademanee A, Wang S.
    Hematol Oncol; 2017 Sep; 35(3):281-287. PubMed ID: 26928577
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.
    Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Bridger G, Calandra G.
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1578-86. PubMed ID: 19896082
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
    Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A, Martino M, Iacopino P, Milone G, Tedeschi P, Coluzzi S, Nuccorini R, Pascale S, Di Nardo E, Olivieri A.
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):241-9. PubMed ID: 21791194
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.
    Choi HY, Yong CS, Yoo BK.
    Ann Pharmacother; 2010 Jan; 44(1):117-26. PubMed ID: 20009003
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.
    Jantunen E, Varmavuo V.
    Expert Opin Biol Ther; 2014 Jun; 14(6):851-61. PubMed ID: 24673120
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.
    Basak GW, Jaksic O, Koristek Z, Mikala G, Mayer J, Masszi T, Labar B, Wiktor-Jedrzejczak W, Central and Eastern European Leukemia Group (CELG).
    Am J Hematol; 2011 Jul; 86(7):550-3. PubMed ID: 21674573
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
    Yuan S, Nademanee A, Kaniewski M, Palmer J, Shayani S, Wang S.
    Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.